Study of Bone Marrow Derived Stem Cell Treatment for Retinal and Optic Nerve Damage

What this Trial Is About

Researchers are evaluating the use of autologous bone marrow derived stem cells BMSC to treat vision loss caused by retinal or optic nerve damage that is typically considered irreversible. The study focuses on conditions such as macular degeneration, hereditary retinal dystrophies like retinitis pigmentosa and Stargardt disease, ischemic or physical retinal damage, as well as optic nerve damage from glaucoma, ischemic optic neuropathy, optic atrophy, and other related diseases. Participants will receive injections of their own stem cells isolated from bone marrow using standard medical and surgical procedures. These injections may be given retrobulbarly, subtenon, intravitreal, intraocular, subretinal, and intravenously to one or both eyes. The treatment is provided in a single group format, and patients will be monitored for 12 months following the procedure. During the 12-month follow-up, participants will undergo comprehensive eye exams including imaging and diagnostic ophthalmic tests. Researchers will measure changes in visual acuity, visual fields, and optical coherence tomography results from before the procedure to 12 months after. Safety and treatment effects will be closely monitored through these assessments to evaluate the potential benefits and risks of the stem cell therapy.

Stem Cell Ophthalmology Treatment Study II